Abstract
The value of urinary RBP4 in the diagnosis of FSGS and other renal diseases
Highlights
Focal segmental glomerulosclerosis is the predominant subtype of primary glomerular diseases in adults and the commonest cause of chronic renal failure [1]
The SWATH-MS performed on sample pools provided quantitation for 194 (FSGS), 179 (IgAN), 271, 255 and 275 urinary proteins (Confidence Interval (CI) > 95%, FDR
A total of 447 different proteins were identified across all groups of interest, from which 87 proteins were common for each group (Supplementary Table 3). 38 proteins were found to be unique for FSGS, including 4 components of PPAR signaling pathway which is implicated in this condition [12] (Supplementary Table 3). 23 molecules were found to be exclusively secreted into the urine of IgA nephropathy (IgAN) (13% of the total protein content), 37 proteins were specific for chromophobe renal cell carcinoma (chRCC) (14.5% of the total protein content), 33 for clear cell renal cell carcinoma (ccRCC) (11% of the total protein content) and 33 for healthy controls (12% of the total protein content) (Supplementary Table 3)
Summary
Focal segmental glomerulosclerosis is the predominant subtype of primary glomerular diseases (primary glomerulopathies, PGs) in adults and the commonest cause of chronic renal failure (chronic kidney disease, CKD) [1]. The precise diagnosis of FSGS is based entirely on kidney biopsy that is an aggressive procedure associated with risk of complications [1]. There are no molecular diagnostic strategies available for FSGS that could serve as a non-invasive alternative to renal biopsy. Urinary proteome comprises a valuable source of biomarkers of kidney diseases, as much of the proteins come directly from the kidneys and reflect their actual physiological status. Urinary proteins are relatively stable comparing to the proteins of sera, and are more desired as biomarkers due to a non-invasive way of urine collection [3]. Urinary proteins proposed hitherto as possible candidates of chronic kidney diseases seemed to outperform the ‘biomarkers’ found in the blood [4]. Unequivocal diagnosis of FSGS can only be made with a renal biopsy, which is an invasive, risk-associated medical procedure. This study examines the urinary proteome of FSGS patients and reference groups, in order to identify urinary protein expression alterations indicative of FSGS
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call